Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - ashpublications.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia
L Wang, K Pearson, JE Ferguson… - British journal of …, 2003 - Wiley Online Library
Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …
P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Purpose: To determine the clinical significance of molecular response and relapse among
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
[HTML][HTML] Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
G Martinelli, I Iacobucci, G Rosti, F Pane, M Amabile… - Annals of oncology, 2006 - Elsevier
Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
F Palandri, I Iacobucci, S Soverini, F Castagnetti… - Clinical Cancer …, 2009 - AACR
Purpose: The achievement of a major molecular response (MMolR) at 12 months is a
surrogate marker of progression-free survival in chronic myeloid leukemia patients treated …
surrogate marker of progression-free survival in chronic myeloid leukemia patients treated …
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
Most patients with de novo chronic myeloid leukemia (CML) achieve good responses to
imatinib, but the rate and degree of molecular response is variable. We assessed the …
imatinib, but the rate and degree of molecular response is variable. We assessed the …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …